Estrogens, Conjugated Shortage: What Providers and Prescribers Need to Know in 2026

Conjugated Estrogens Shortage: What Providers and Prescribers Need to Know in 2026

The ongoing supply disruptions affecting Conjugated Estrogens (Premarin) continue to create challenges for clinicians managing menopausal hormone therapy, hypoestrogenism, and related conditions. This briefing provides a clinical overview of the current shortage landscape, prescribing implications, and actionable strategies for maintaining patient care continuity.

Shortage Timeline and Current Status

Conjugated Estrogens have experienced intermittent supply disruptions across multiple formulations:

• Premarin Vaginal Cream (0.625 mg/g, 30 g): Listed on the ASHP drug shortage list as of 2025 due to Pfizer manufacturing delays. Supply remains inconsistent heading into 2026, with no firm resolution date announced.
• Premarin Injection (25 mg vial): Previously on the ASHP shortage list but supply was restored as of September 2025. Availability is expected to remain stable.
• Premarin Oral Tablets (0.3 mg–2.5 mg): Generally available, though regional stock-outs have been reported at higher-volume pharmacies.

Pfizer remains the sole manufacturer of brand-name Premarin. No FDA-approved generic exists for any Premarin formulation in the United States, making this a single-source product with inherent supply vulnerability.

Prescribing Implications

The absence of a true AB-rated generic for Premarin means pharmacists cannot substitute an alternative without a new prescription. Clinicians should proactively address the following:

Therapeutic Alternatives

When Conjugated Estrogens are unavailable, evidence-based alternatives include:

• Estradiol (oral, transdermal, vaginal): The most widely available alternative. Bioidentical 17β-estradiol is available as oral tablets (Estrace, generics), transdermal patches (Climara, Vivelle-Dot, generics), topical gels/sprays (EstroGel, Evamist), and vaginal formulations (Estrace cream, Estring, Vagifem/Yuvafem). Transdermal estradiol may be preferred in patients with elevated thrombotic risk, as it avoids first-pass hepatic metabolism.
• Esterified Estrogens (Menest): Synthetic estrogen tablets available in comparable dose strengths (0.3 mg, 0.625 mg, 1.25 mg, 2.5 mg). Note that esterified estrogens are not bioequivalent to conjugated estrogens and require a new prescription.
• Synthetic Conjugated Estrogens (Cenestin, Enjuvia): Plant-derived synthetic formulations containing a similar estrogen profile to Premarin. These are the closest therapeutic equivalents but are also not AB-rated substitutes.
• Bazedoxifene/Conjugated Estrogens (Duavee): A TSEC (tissue-selective estrogen complex) combining conjugated estrogens with a SERM. Eliminates the need for concurrent progestin in women with a uterus. FDA-approved for vasomotor symptoms and osteoporosis prevention.

Dose Conversion Considerations

There is no universally accepted conversion ratio between conjugated estrogens and estradiol. However, commonly used clinical approximations include:

• Conjugated Estrogens 0.625 mg oral ≈ Estradiol 1 mg oral ≈ Estradiol 0.05 mg/day transdermal patch
• Conjugated Estrogens 0.3 mg oral ≈ Estradiol 0.5 mg oral ≈ Estradiol 0.025 mg/day transdermal patch

Individual patient response varies, and dose titration may be necessary.

Concurrent Progestin Therapy

Women with an intact uterus switching estrogen formulations should continue concurrent progestin therapy (e.g., medroxyprogesterone acetate, micronized progesterone) to protect against endometrial hyperplasia and cancer. The exception is Duavee, which includes bazedoxifene for endometrial protection.

Availability Picture

Clinicians can help patients navigate availability by leveraging the following resources:

• Medfinder for Providers — Real-time pharmacy stock lookup. Direct patients to check availability before driving to the pharmacy.
• ASHP Drug Shortage Database — For clinical shortage updates and estimated resolution timelines.
• Independent pharmacies — Often have separate wholesaler relationships and may carry stock when chain pharmacies do not.
• Compounding pharmacies — May be able to prepare conjugated estrogen cream formulations for patients who cannot access Premarin Vaginal Cream.

Cost and Access Considerations

Conjugated Estrogens carry a significant cost burden, particularly for uninsured or underinsured patients:

• Premarin tablets (0.625 mg, 30 ct): ~$278–$285 cash price; as low as $99 with discount coupons
• Premarin Vaginal Cream (30 g): ~$578 cash price; as low as $237 with coupons
• Premarin Injection (25 mg vial): ~$411 per vial

Key patient assistance resources include:

• Pfizer Co-Pay Savings Card (PfizerForAll): Commercially insured patients may pay as little as $25 per fill.
• Pfizer RxPathways: For uninsured and low-income patients, Pfizer offers free or reduced-cost medication through their patient assistance program.
• Discount cards: GoodRx, SingleCare, and other platforms offer significant savings on Premarin.

Regulatory Update: Boxed Warning Changes

In November 2025, the FDA initiated removal of boxed warnings for cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products. The boxed warning for endometrial cancer with estrogen-alone therapy is retained. This labeling change may reduce barriers to prescribing and improve patient acceptance of hormone therapy.

Tools and Resources for Providers

• Medfinder for Providers — Help patients locate medications in stock
• Provider's guide to helping patients find Conjugated Estrogens
• Provider's guide to helping patients save money on Conjugated Estrogens
• ASHP Drug Shortage Resource Center
• Pfizer RxPathways (pfizerrxpathways.com)

Looking Ahead

The Conjugated Estrogens supply situation is expected to remain variable through 2026, particularly for the vaginal cream formulation. No generic approval appears imminent. Clinicians should maintain familiarity with alternative estrogen formulations, proactively discuss switching options with patients, and utilize real-time availability tools to minimize treatment disruptions.

Final Thoughts

Managing patients through a drug shortage requires proactive communication, clinical flexibility, and awareness of available resources. Conjugated Estrogens remain an important therapy for many patients, but the current supply landscape demands that providers have backup plans ready. Use Medfinder for Providers to streamline pharmacy availability checks, and keep patients informed about cost-saving options and alternative therapies.